MARKET

PIRS

PIRS

Pieris Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.940
+0.050
+1.73%
After Hours: 2.940 0 0.00% 16:00 12/03 EST
OPEN
2.930
PREV CLOSE
2.890
HIGH
2.980
LOW
2.850
VOLUME
261.23K
TURNOVER
--
52 WEEK HIGH
4.300
52 WEEK LOW
1.600
MARKET CAP
164.55M
P/E (TTM)
-5.9951
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
25 Best U.S. Cities to Live With Asthma
In this article we take a look at the 25 best U.S. cities to live with asthma. Click to skip ahead and jump to the 10 best U.S. cities to live with asthma. Navigating through life with asthma can be a life-long challenge in itself. Sometimes it becomes very important to constantly monitor your surroundings […]
Insider Monkey · 11/24 19:29
Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
/ , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences:
ACCESSWIRE · 11/10 13:01
Pieris Pharmaceuticals: Q3 Earnings Insights
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected after the company reported Q3 results.Quarterly Results Earnings per share were down 420.00% over the past year to ($0.26), which missed the estimate of ($0.13).Revenue of $2,939,000 declined by 80.58% year over year, which missed the estimate of $9,790,000.Guidance Pieris Pharmaceuticals hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: Nov 04, 2020View more earnings on PIRSTime: 08:00 AMET Webcast URL: https://www.pieris.com/news-and-events/upcoming-eventsPrice Action Company's 52-week high was at $4.3052-week low: $1.60Price action over last quarter: down 20.89%Company Overview Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343 and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm is functioned through the region of United States.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 4, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 11/04 12:58
Pieris Pharmaceuticals EPS misses by $0.13, misses on revenue
Pieris Pharmaceuticals (PIRS): Q3 GAAP EPS of -$0.26 misses by $0.13.Revenue of $2.94M (-80.6% Y/Y) misses by $8.78M.Press Release
Seekingalpha · 11/04 12:05
Pieris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
ACCESSWIRE · 11/04 12:01
Pieris Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 4, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 4, 2020 at 8:00 AM Eastern Time.
ACCESSWIRE · 11/04 11:15
Pieris Pharmaceuticals to Host Third Quarter 2020 Investor Call and Corporate Update on November 4, 2020
BOSTON, MA / ACCESSWIRE / October 28, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2020 investor call on Wednesday, November 4, 2020 at 8:00 AM EST to discuss financial results and provide a corporate update.
ACCESSWIRE · 10/28 12:00
Hedge Funds Are Crazy About Pieris Pharmaceuticals, Inc. (PIRS)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our stance on March 25th after seeing unprecedented fiscal and monetary stimulus unleashed by the Fed and the Congress
Insider Monkey · 10/05 15:40
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PIRS. Analyze the recent business situations of Pieris Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PIRS stock price target is 7.67 with a high estimate of 9.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 144
Institutional Holdings: 38.06M
% Owned: 67.99%
Shares Outstanding: 55.97M
TypeInstitutionsShares
Increased
23
3.69M
New
23
-2.16M
Decreased
35
2.80M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.08%
Pharmaceuticals & Medical Research
+0.39%
Key Executives
Chairman/Independent Director
James Geraghty
Chairman/Independent Director
james Geraghty
President/Chief Executive Officer/Director
Stephen Yoder
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance/Treasurer
Thomas Bures
Senior Vice President/Chief Scientific Officer
Hitto Kaufmann
Senior Vice President/General Counsel/Secretary
Ahmed Mousa
Senior Vice President
Ingmar Bruns
Senior Vice President
Eckhard Niemeier
Senior Vice President
Shane Olwill
Independent Director
Ann Barbier
Independent Director
Peter Kiener
Independent Director
Christopher Kiritsy
Independent Director
Michael Richman
Independent Director
Maya Said
Independent Director
Matthew Sherman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PIRS
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Pieris Pharmaceuticals Inc stock information, including NASDAQ:PIRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PIRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PIRS stock methods without spending real money on the virtual paper trading platform.